Last $63.70 USD
Change Today +0.60 / 0.95%
Volume 1.2K
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

astrazeneca plc (AZNCF) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/28/14 - $69.21
52 Week Low
07/3/13 - $47.45
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ASTRAZENECA PLC (AZNCF)

astrazeneca plc (AZNCF) Details

AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. Its principal products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL for control of hypertension and for use in heart failure and angina; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders. The company's principal products also comprise Pulmicort for treating asthma and chronic obstructive pulmonary disease (COPD); Symbicort for maintenance treatment of asthma and COPD; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. In addition, it has 99 pipeline projects, which include 85 in clinical development and 14 either approved, launched, or filed. The company markets its products to primary care and specialist doctors through distributors or local representative offices. AstraZeneca PLC has collaboration agreements with Amgen, Inc. and FibroGen, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.

51,500 Employees
Last Reported Date: 03/20/14
Founded in 1992

astrazeneca plc (AZNCF) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: 3.0M GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 259.0K GBP
Compensation as of Fiscal Year 2013.

astrazeneca plc (AZNCF) Key Developments

AstraZeneca and UK's Medical Research Council Enter into Five-Year Early Drug Discovery Collaboration

AstraZeneca announced that it had entered into a five-year early drug discovery collaboration with the UK Medical Research Council (MRC). A new research facility, the AstraZeneca MRC UK Centre for Lead Discovery, will be set up as part of the new collaboration, which is expected to be completed in 2016. Within the scope of the collaboration, the MRC is committed to fund up to 15 new screening projects annually. Meanwhile, AstraZeneca is to grant access to over two million molecules in its compound library. The five-year time frame was set up as an initial period for the project, part of which is set to be initiated within AstraZeneca's existing research facilities next year. However, the new centre will be located within the Cambridge Biomedical Campus where it is to provide screening facilities and review research proposals. As part of the deal, AstraZeneca has secured the rights to enter into a potential negotiation to license drugs that are been developed as a result of the collaboration, according to its therapeutic areas of interest. Only after this option has been explored by the firm can MRC and its scientists "negotiate with other parties".

AstraZeneca and MRC Enter Strategic Collaboration to Create New Centre for Early Drug Discovery in Cambridge, UK

The Medical Research Council (MRC) and AstraZeneca announced that they have entered into a groundbreaking collaboration aimed at better understanding the mechanisms of human disease. The collaboration will see the creation of a joint research facility at AstraZeneca's new RandD centre in Cambridge in the UK. The AstraZeneca MRC UK Centre for Lead Discovery will sit within the new AstraZeneca site at the Cambridge Biomedical Campus, due to be completed in 2016. It will see world class MRC-supported researchers working side-by-side with scientists in AstraZeneca's high throughput screening group, identifying new methods to better understand a range of diseases and potential treatment options. As part of the collaboration, which will run for an initial period of five years, academic researchers will benefit from unprecedented access to over two million molecules in AstraZeneca's compound library, as well as its high throughput screening facilities at the new site. Research proposals will be submitted to the MRC that will independently assess and select the best scientific proposals from a broad range of therapy areas and diseases. The MRC will fund up to 15 screening projects per year to be carried out at the Centre for Lead Discovery. AstraZeneca will have the first option to enter a negotiation to license any resulting drug discovery programmes of relevance to the company's therapeutic areas of interest. If this option is not used, the academics can negotiate with other parties.

AstraZeneca Forms Research Partnership with Shenzhen University Health Science Center

AstraZeneca has announced the formation of a research partnership with Shenzhen University Health Science Center. The partnership will focus on pre-clinical research of treatments targeting chronic kidney disease (CKD) by bringing together scientists from both organisations. The first target of the partnership is expected to be potential treatments for diabetic nephropathy.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AZNCF:US $63.70 USD +0.60

AZNCF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $48.55 USD +0.43
Amgen Inc $115.46 USD -0.08
Biogen Idec Inc $290.54 USD -0.94
Bristol-Myers Squibb Co $49.46 USD +0.35
Eli Lilly & Co $60.43 USD +0.47
View Industry Companies

Industry Analysis


Industry Average

Valuation AZNCF Industry Range
Price/Earnings 31.2x
Price/Sales 3.1x
Price/Book 3.4x
Price/Cash Flow 31.4x
TEV/Sales 3.1x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at